Home » Vertex’s Kaftrio Nabs EU Approval as Combination Treatment for Cystic Fibrosis
Vertex’s Kaftrio Nabs EU Approval as Combination Treatment for Cystic Fibrosis
April 29, 2021
Vertex Pharmaceuticals has secured an expanded indication in the EU for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with additional ivacaftor for treating patients with certain mutations in the cystic fibrosis transmembrane conductance regulator gene.
Approval was supported by positive results from three global phase 3 studies enrolling 768 cystic fibrosis patients.
The triple combination therapy plus ivacaftor was previously approved for this indication in the U.S. and Australia, where Kaftrio is marketed as Trikafta.
Upcoming Events
-
21Oct